NBER WORKING PAPER SERIES

COMPARING 2SLS VS 2SRI FOR BINARY OUTCOMES AND BINARY EXPOSURES
Anirban Basu
Norma Coe
Cole G. Chapman
Working Paper 23840
http://www.nber.org/papers/w23840

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
September 2017

Basu acknowledges support from NIH research grants RC4CA155809 and R01CA155329. Coe
acknowledges support from National Institute of Nursing Research grant NIH 1R01NR13583 (PI:
Van Houtven). Chapman acknowledges support from SMT Inc. (PI: Schooley) and the Institute
for Healthcare Improvement (PI: Cozad). We thank two anonymous reviewers for their very
useful comments. Opinions expressed are ours and do not reflect those of the University of
Washington or the NBER. All errors are our own. The views expressed herein are those of the
authors and do not necessarily reflect the views of the National Bureau of Economic Research.
NBER working papers are circulated for discussion and comment purposes. They have not been
peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies
official NBER publications.
¬© 2017 by Anirban Basu, Norma Coe, and Cole G. Chapman. All rights reserved. Short sections
of text, not to exceed two paragraphs, may be quoted without explicit permission provided that
full credit, including ¬© notice, is given to the source.

Comparing 2SLS vs 2SRI for Binary Outcomes and Binary Exposures
Anirban Basu, Norma Coe, and Cole G. Chapman
NBER Working Paper No. 23840
September 2017
JEL No. C26,I10,I18
ABSTRACT
This study uses Monte Carlo simulations to examine the ability of the two-stage least-squares
(2SLS) estimator and two-stage residual inclusion (2SRI) estimators with varying forms of
residuals to estimate the local average and population average treatment effect parameters in
models with binary outcome, endogenous binary treatment, and single binary instrument. The
rarity of the outcome and the treatment are varied across simulation scenarios. Results show that
2SLS generated consistent estimates of the LATE and biased estimates of the ATE across all
scenarios. 2SRI approaches, in general, produce biased estimates of both LATE and ATE under
all scenarios. 2SRI using generalized residuals minimizes the bias in ATE estimates. Use of
2SLS and 2SRI is illustrated in an empirical application estimating the effects of long-term care
insurance on a variety of binary healthcare utilization outcomes among the near-elderly using the
Health and Retirement Study.
Anirban Basu
Departments of Health Services,
Pharmacy and Economics
University of Washington
1959 NE Pacific St
Box - 357660
Seattle WA 98195
and NBER
basua@uw.edu
Norma Coe
University of Pennsylvania
Perelman School of Medicine
Division of Medical Ethics and Health Policy
423 Guardian Drive
Philadelphia, PA 19104
and NBER
nbcoe@pennmedicine.upenn.edu

Cole G. Chapman
University of South Carolina
915 Greene Street, 303C
Columbia SC 29208
CHAPMAC8@mailbox.sc.edu

1. INTRODUCTION
Instrumental variables (IV) methods are used to obtain causal estimates of the effects of
endogenous variables on outcomes using observational data. These methods mediate
potential bias from unmeasured confounders affecting observed treatment through
identifying and specifying an instrumental variable, which may represent a ‚Äúnatural
experiment‚Äù affecting treatment through satisfying two principal assumptions: the
instrument is sufficiently correlated with the endogenous variable (strength), and the
instrument is uncorrelated with the error term in the outcome equation (validity). IV
methods are usually implemented using a two-stage approach where the first-stage
estimates an expectation of the endogenous variable conditional on measured
confounders and one or more instrumental variables. The second stage model then
predicts outcomes as a function of the estimated treatment values from the first-stage,
measured confounders, and potentially other control variables.
In what has been popularly dubbed as the two-stage least-squares (2SLS) approach, the
first and second stage models are parametrized using ordinary least squares regression,
where the model fit is chosen through minimizing the sum of squared residuals from linear
models. The 2SLS approach is a special case of the more general two-stage predictor
substitution (2SPS) method, which follows the procedure described above but may apply
alternative methods for estimating first- and second-stage models. Alternatively, one can
obtain the residuals from the first stage regression and then run the second stage
regression with the original endogenous variable, observed confounders and the residuals
from the first stage as an added covariate. This approach, known as the two-stage residual
inclusion (2SRI) approach, is analogous to the 2SLS approach when both first- and secondstage models are linear.
These estimation methods were originally derived in a linear setting with continuous
endogenous treatments and continuous outcome measures but are often applied to what
may be considered an inherently non-linear setting, such as with binary treatment or
outcome measures. However, when treatment (exposure) or outcome is binary and
therefore has a conditional expectation that follows a probability scale, a non-linear model
featuring a convenient cumulative density function (CDF) is often used to model the
conditional mean of the treatment indicator in the first-stage or outcome in the secondstage. Popular approaches include using probit or logit regression models.

3

However, complications arise when the outcome in the second stage is binary, and analysts
consider using CDF-based non-linear models. It is well established that the 2SPS approach
produces biased estimates of the population average treatment effect (ATE) in these
scenarios (Blundell and Powell 2001; Terza et al. 2008). Under full parametric assumptions
of joint-normality, bi-variate probit models can be used to model the two stages
simultaneously (Bhattacharya et al. 2006).
Alternatively, it has been suggested that nonlinear 2SRI is the appropriate approach for
estimation when first- or second-stage models have a dependent variable that is binary or
otherwise suited for non-linear regression; especially when full parametric assumptions,
where statistical joint distribution of error terms of the exposure and outcomes are
specified, are not wanted (Blundell and Powell 2003, 2004; Terza et al. 2008). Nonlinear
2SRI methods identify the ATE through relying on the concepts that support control
function methods (Blundell and Powell 2003, 2004), which were developed in the context of
continuous endogenous variables. However, the applicability of nonlinear 2SRI to models
with binary endogenous treatments remains contentious.
An important source of further complexity and potential confusion in comparisons of these
estimates is that the specific treatment effect parameter identified by the 2SLS or 2SRI
approaches may differ and depends on whether treatment effects are heterogeneous
across the population and vary across levels of observed or unobserved confounders (aka
essential heterogeneity). In such a situation, it is well‚Äìestablished that traditional IV
approaches such as 2SLS identify an average treatment effect across only the subgroup of
‚Äúmarginal‚Äù individuals whose treatment choices were affected by changes in the specified
instrumental variable(s) (Heckman 1997; Heckman et al. 2006, Basu et al. 2007). When the
instrumental variable is binary (which is the focus of this paper), this effect is known as the
local average treatment effect (LATE) (Imbens and Angrist 1994). Both 2SLS and the
analogous strictly linear application of 2SRI will generate consistent estimates of LATE as
long as the linear mean model specifications in both stages are correct.1
Terza et al. (2007, 2008) claimed that nonlinear 2SRI, but not 2SLS or 2SPS, produced
consistent estimates of ATE in models with inherently nonlinear dependent variables.
However, it is not clear which treatment effect parameter is being estimated under a 2SRI

1

The LATE effect is non-parametrically identified in a 2SLS setting within any cell defined by levels of all
observed covariates X (Imbens and Angrist 1994). However, in a regression setting with many X‚Äôs, where a full
saturated model is typically not used, the consistency of estimating LATE would rely on the appropriateness of the
linear model specification.

4

approach for a binary treatment. Particularly in applications with binary IVs, the 2SRI
approach relies on functional form assumptions for identification (as explained below) that
are difficult to test in most applied setting and many analysts, especially economists, have
favored the 2SLS approach regardless of whether treatment and outcome are continuous
or binary. As such, many questions remain about the best approaches to IV estimation with
such data. On the one hand, linear probability models may not provide a good fit to the
data, especially when treatment or outcome variables are ‚Äúrare‚Äù or otherwise imbalanced
in nature, which in turn may lead to imprecise estimates. On the other hand, probit and
logit models may provide a better fit to observed data overall but generate biased
estimates depending on the support of the residual distribution (across all X‚Äôs).
For example, Chapman and Brooks showed that small changes to the simulation settings of
Terza et al. (2007) resulted in different results and conclusions about the properties of 2SLS
and 2SRI. They showed that 2SLS produced consistent estimates of LATE across alternative
scenarios while 2SRI estimates were not consistent for either ATE or LATE. However, the
evidence produced by Chapman and Brooks is limited in that their scenarios all had
treatment and outcome rates near 50%, a setting that may have inadvertently favored the
2SLS method.
Moreover, there is a debate in the health econometrics literature about the right form of
the residual to be used in 2SRI approaches. Garrido et al. (2012) compared results from
2SRI models with different versions of residuals when applied to health expenditure data.
They found that results varied widely depending on the type of residuals they use in the
second stage. They raised the concern that raw residuals may not be the right control
function variable. However, there is no theoretical rationale as to why different forms of
the residual matter, nor did they do any simulations to show which one is better.
In this paper, we try to provide theoretical and empirical evidence to inform these
debates.2 We study a simple scenario with a binary outcome, a binary treatment that is
made endogenous by a continuous unobserved confounder, binary instrument, and a
binary measured confounder. After a theoretical discussion on the expected effects of
alternative estimators, we study the properties of 2SLS and alternative 2SRI methods

There are other forms of estimators that deal with a binary outcome and a binary endogenous
treatment model, such as a GMM approaches (McCarthy and Tchernis 2011) and semi-parametric
estimators (Abadie 2003; Abrevaya et al. 2009, Chiburis 2010; Shaikh and Vytlacil 2011). However,
these estimators are not as popular as the 2SLS and the 2SRI approaches and so we do not cover
them in this paper.
2

5

across a range of scenarios where the rarity of the treatment and/or the outcomes are
varied using extensive Monte-Carlo simulation exercises.
Results show that the 2SLS method with binary IV produced consistent estimates of LATE
across the entire range of rarity for either treatment or the outcome. The rarity of either
did not affect the coverage probabilities of these estimators. In contrast, the 2SRI approach
with any residuals studied was a biased estimator for LATE. In principle, nonlinear 2SRI
estimators are designed to estimate the ATE parameter. However, 2SRI estimates of ATE
were also generally biased, with the level of bias varying by residual form and outcome
rarity. Amongst 2SRI models, those using generalized residuals were most often least
biased in estimating ATE, though 2SRI with Anscombe residuals generated less biased
estimates in scenarios with very rare outcomes (<5%). Implications of these results are
discussed.
Finally, we examined the implications of model choice using an empirical setting that
resembles the simulated scenario with endogenous binary treatment, binary outcomes,
and binary observable confounders. The alternative instrumental variable methods were
applied to evaluate the effect of long-term care insurance on a variety of health care
utilization outcomes using tax treatment as an instrument for long-term care insurance
holding, as has been validated in the literature (Goda 2011; Konetzka, et al. 2014, Coe,
Goda and Van Houtven 2015). The results from applying the alternative estimators are
discussed in the context of our simulation results.

2. ECONOMETRIC THEORY & METHODS
Consider the binary structural response model
yi = 1{yi* >0} ,

(1)

where the latent variable yi* follows a linear model of the form
yi* = xiŒ≤ + ui,

(2)

where xi is a row vector of covariates and ui is a stochastic disturbance term for individual i.
Throughout this section, bold-face is used to represent a vector. If ui is independent of xi, a
single index regression model such as:

6

E(yi |xi) = G(xiŒ≤)

G(a) = Pr{ui > -a)

(3)

can be used to obtain consistent estimates of Œ≤. However, it may often be the case that ui is
not independent of xi because some component of xi , say di, is determined jointly with yi*
such that
xi = (di, wi), yi = 1{diŒ≤1 +wiŒ≤2 + ui>0}, and di ÔÅû ui,

(4)

where ÔÅû indicates statistical independence. Let the reduced form of di, which we denote to
be the endogenous treatment variable, be given as
di

= E(di|wi, zi) + vi
= Œª(wi, zi) + vi

(5)

where zi = vector of instrumental variables, Œª is the true function through which di is
determined by wi and zi, vi is a stochastic disturbance term, and E(vi | wi, zi) = 0 by
construction. It is assumed throughout that expectation of d is a non-trivial function of z
given w.
For evaluation research, interest generally lies in estimating Œ≤ parameters or, more
specifically, the components of Œ≤ that represent the causal effect of an exogenous shift in
treatment, di, on the response probabilities. The interpretation of those parameters of
interest then must be considered. The broadest and perhaps most intuitive treatment
effect parameter is the average treatment effect (ATE), which represents the mean change in
an outcome that would be realized if everyone in a target population changed from not
receiving treatment to receiving treatment. The ATE can be written as
ATE(w)

= ‚à´ùë¢‚ààùëà|ùíò{E(yi |ùê∞ùê¢ , ui , di = 1) ‚àí E(yi |ùê∞ùê¢ , ui , di = 0)} ‚àô dF(u|w)
= G(Œ≤1 +wiŒ≤w) - G(wiŒ≤w)

(6)

where ATE (w) represents the conditional average treatment effect for a sample, which may
be distinct in the mix of characteristics w.
If it is the case that treatment effects are heterogenous across the population and this
heterogeneity is related to treatment choice (i.e., essential heterogeneity), then treatment
effectiveness will vary over levels of ui when components of w are unmeasured by the
researcher (i.e., there are unmeasured confounders). As a result, identification of ATE will

7

require strong assumptions. First, the ATE can be estimated through identification of the
function represented by G(.), which is to akin to identifying the full parametric distribution
of ui. In the absence of full parametric assumptions, the ATE can be identified in special
cases using instrumental variables methods, where the specified IV(s) fully identify the
conditional distribution of ui | vi, which can then be integrated over the distribution of vi
identified in the IV-based first-stage model. More simply put, the specified IV(s) must be
considered as potentially influencing treatment choice for all types of individuals in the
sample, defined by their levels of observed and unobserved characteristics. These IV
assumptions may be particularly difficult to satisfy when a single binary instrument is used,
as only two points of support in the distribution of vi are identified non-parametrically.
More generally, as Imbens and Angrist (1994) have shown, the IV effect estimated using a
single binary IV, zi, is referred to as the local average treatment effect (LATE) and is given as:
LATE(w) = (E(yi |wi, zi =1) - E(yi |wi, zi =0)) / (E(di |wi, zi =1) - E(di |wi, zi =0))

(7)

The LATE reflects the average causal effect of di on the probability of yi among those
(marginal) individuals whose treatment statuses would likely change with a change in the
level of the instrumental variable (Angrist & Imbens 1994, 1996; Heckman 1997). The LATE
parameter is only ‚Äúlocally‚Äù interpretable in the context of the instrument specified. Even
with very strong instruments that lead all patients in the sample to be marginal, LATE will
not often converge to the ATE because, unlike randomization, the instrument may put
more weight on some marginal patient than others. Therefore, since it is often difficult to
identify the marginal patients directly (i.e., to know for whom the instrument affected
choice), it may also be difficult to understand to whom the estimate applies (Heckman
1997; Newhouse and McClellan, 1998). In some cases where a binary IV is related to a
specific policy, LATE may be interpretable as the effect of changing di among those
individuals who would be induced to change their treatment status by the policy (Heckman
et al. 2006). Naturally, if the true treatment effect is constant then the true LATE and ATE
are the same.
The following discussion focuses on three popular approaches for estimation of mean
effects on response probabilities from an instrument-driven exogenous shift in the
treatment di: the fully parametric bivariate probit (BVP) model, the semi-parametric
residual inclusion (2SRI) approach, and the linear two-stage least squares (2SLS) approach.
Each of these methods employs different assumptions and attempt to identify different
parameters. In fact, Chiburis et al. (2012) have argued that many of the documented

8

differences in the treatment effect estimates from 2SLS and bi-variate probit models in the
literature may be driven by the fact that they are estimating different parameters, to begin
with. We now look at these estimators in detail.

2.1 Approach 1 (Fully parametric): e.g. Bivariate-Probit
If the joint distribution of the structural error term ui and the reduced form error term vi
were parametrically specified (e.g., Gaussian), and Œª(wi, zi) is parametrically specified, then
under some normalization of the Var(ui) (Blundell and Smith 1986),
E(yi | di, wi, vi)

= Pr( ui > -diŒ≤1 - wiŒ≤2 |vi)
= ÔÅÜ(diŒ≤1 +wiŒ≤2 +œÅvi),

(8)

where œÅ is the vector of population regression coefficients of ui on vi. The parameters Œ≤, Œª(.)
and œÅ can be estimated using maximum likelihood estimation. When both yi and di are
binary, this approach can be implemented using a bivariate probit regression (Heckman
1978). However, bivariate probit models can be sensitive to heteroscedasticity and are
usually more robust when treatment probabilities approach 0 or 1 (Chiburis et al. 2012). If
the underlying distributions are correctly specified, this method structurally recovers the
average treatment effect (ATE) parameter since ui | vi, identified through the IV, is
structurally linked to ui through the parametric assumption.
The sample analog for the population treatment effect parameter identified by this
approach is given by:
ÃÇùüê + œÅÃÇ ‚àô vÃÇi ) - ÔÅÜ(0 ‚àô Œ≤ÃÇ1 + ùê∞ùê¢ ùõÉ
ÃÇùüê + œÅÃÇ ‚àô vÃÇi ) }},
Eùêñ {EvÃÇ {ÔÅÜ(1 ‚àô Œ≤ÃÇ1 + ùê∞ùê¢ ùõÉ

(9)

where ‚àôÃÇ indicates that these quantities have been estimated from the data at hand.

2.2 Approach 2 (Semi-parametric): e.g 2SRI
The semi-parametric approach uses estimates of the reduced form error term, vi, to control
for endogeneity of di in the outcomes structural model (Blundell and Powell 2004). The
identification of Œ≤1 and the distribution functions of the error term, ui, is through

9

distributional exclusion restrictions, the first of which requires that the dependence of ui on
each of di, wi and zi are completely characterized by the reduced form error vector vi:
ui | di, wi, zi

~ ui | di, wi, vi
~ ui | vi

( 10 )

Under this assumption,
E(yi |di, wi, vi) = Pr[ui ‚â§ - diŒ≤1 - wiŒ≤2 | di, wi, vi]
= F(diŒ≤1 + wiŒ≤2 | vi).

( 11 )

where F(.) is the conditional c.d.f. of -ui given vi.
The marginal distribution function G(.) with respect to -ui could be identified using a control
function approach such as (Blundell and Powell 2004):
G(diŒ≤1 + wiŒ≤2) = ‚à´ F(dùëñ Œ≤1 + ùê∞ùíä ùõÉùüê , v1 )Hùëâ ,

( 12 )

where Hv is the distribution function of v. Consequently, ATE can be identified using (6).
Note that, unlike the fully parametric approach, one can be agnostic about the parametric
distribution of ui and vi as long as the distributional exclusion criterion is met. However,
Blundell and Powell‚Äôs (2003) identification relies on a continuous vi. Moreover, the
identification of ATE relies on the fact that the error term in the outcomes model is
additively separable. These conditions allow for a counterfactual to be determined without
the need for any additional functional form assumptions given that the Œ≤ are consistently
estimated. However, in non-linear models, such as those in (2), these counterfactuals
inherently depend on the functional form assumption of the control function.
For example, in practice, this approach is implemented through ‚Äúresidual inclusion‚Äù, which
follows estimating the error term in the first‚Äìstage regression and then including these
estimated residuals as a covariate in the second-stage outcomes regression. A recycled
predictions approach can then be used to recover the marginal effect of di on E(yi).
However, when implementing this approach for a binary treatment variable, the residuals
from the first stage would always be positive for treatment recipients and negative for nonrecipients. Hence, in a non-linear outcomes model, the conditional treatment effect,
conditional on any level of the estimated vi (say, vÃÇùëñ ), must be obtained via extrapolation.

10

Figure 1 illustrates this idea for a group of individuals with the same wi, which is kept
implicit, but different values of zi. Suppose the residuals among treatment recipients are
0.1, 0.2, 0.3, 0.4, 0.7 and those among non-recipients are -0.1, -0.2, -0.3, -0.4, -0.7.
Conditional on a positive level of the residual vi+, E(y|d=1, vÃÇùëñ +) = E((y1| vÃÇùëñ +) is obtained
from the data where y1 is the potential outcome under treatment. However, the
counterfactual outcome, i.e. th,e corresponding potential outcome y0 under no treatment,
is not observed in the data as there are no non-recipients that have a positive level of the
residual by construction. The counterfactual outcome has to be obtained via extrapolation
of the functional specification of F(), which in turn determines the estimate for Œ≤1. Figure
1(a) illustrates this extrapolation. The overall treatment effect is then obtained by averaging
the conditional treatment effects obtained over the distribution of vÃÇùëñ .
Symmetry in the distribution of vÃÇùëñ , to the extent that it can be attained, can facilitate this
extrapolation. Most forms of residuals used in non-linear settings attempt to mimic a
normal distribution. Alternate forms of residuals, such as standardized, deviance,
Anscombe, and generalized (Gourieroux et.al., 1987), may also be used in the residual
inclusion approach and have been explored Garrido et al. 2012). When estimated by a
nonlinear approach, such as probit or logit, raw-scale residuals for a binary treatment
variable will always lie between 0 and 1 in absolute values. Therefore, each type of residual
transformation is likely to spread the support of the residual distribution on the real line.
For example, if predicted Pr(d|z) = 0.4 and 0.7 for two observations with d = 1, then the
raw-scale residuals will be 0.6 and 0.3 respectively, but the standardized residuals (= (d ‚Äì
pÃÇ(z))/‚àö( pÃÇ(z)(1 ‚àí pÃÇ(z)) ) will be 1.22 and 0.65 respectively. Consequently, standardized
residuals may provide a better fit to the outcomes data and increase the robustness of
extrapolations. For example, when the treatment is rare, the raw-scale residuals on either
the negative or the positive side are likely to be far away from zero. Transformation can
help these residuals to spread out, so as to increase accuracy when estimating the
functional form of the outcome conditional on these residuals. A priori, it is difficult to
predict what form of residuals from a binary treatment model would best approximate the
non-separable error term in the outcomes equation.
It is worth reiterating that a central problem, beyond the issue of non-overlap in support of
vÃÇùëñ as discussed above, when the instrumental variable is also binary is that only two points
on the support of vÃÇùëñ are identified for any level of w. Model fit and extrapolation is based
only on those two points in the support for vÃÇùëñ .

11

2.3 Approach 3 (Non-parametric): e.g. 2SLS
Distinct from BVP and 2SRI approaches discussed above, which are designed to identify the
ATE, a 2SLS approach is designed to estimate the LATE parameter. A 2SLS approach
attempts to estimate the LATE from the data non-parametrically by estimating the slope of
outcomes and exposure, conditional on the instrument. In the case of a single binary
instrument, this slope is based upon the two points of support identified by the two levels
of the instrument. That is, it plugs in the sample analogs of the numerator and the
denominator in the LATE parameter defined above. However, this process assumes that
the mean outcomes and the exposure models are linear in terms of wi.3 When one or both
of these linear specifications are violated, 2SLS may be a biased estimator for the outcome
probabilities (Horace and Oaxaca 2006). While this could, in turn, induce bias in the
estimation of LATE, some have suggested that risk of such bias is minimal in many applied
settings and concerns are exaggerated. (Angrist, Fernandez-Val 2001)
The 2SLS approach of linear IV models can be viewed as a special case of control function
methods (Telser 1964), where both first and second stage regressions are linear. However,
since 2SLS approaches rely only on mean‚Äìindependence requirements, and not on the full
conditional independence of the distribution as in (8), demands the ‚Äúcorrect‚Äù specification
of the first-stage to provide consistent estimates of the second-stage parameters (Blundell
and Powell, 2004). However, this requirement seems to apply mostly for the estimation of
ATE; as the LATE value is not necessarily equivalent or determined by the true structural
parameters under essential heterogeneity. It is unclear how violation of this requirement
affects the estimation of LATE. We expect that for a binary treatment in the first stage, a
linear approximation of the conditional mean is likely to be most appropriate when the
mean treatment is close to 50%. Chapman and Brooks (2016) demonstrates that this is the
case through their simulations.
These discussions establish the rationale for the simulations in this paper. It is conjectured
that 2SRI approach applied to binary endogenous variables can produce biased results
when extrapolations are not appropriate. Alternative versions of the residuals could
improve the performance of 2SRI approaches through mutating the scale of the residual
distribution used, which could influence the estimation of the underlying structural
functions through the 2SRI approach as was observed in Garrido et al. (2012). Second,
3

There can certainly be a more elaborate model building exercise that can overcome this problem, but such
exercises are seldom found in the economics and health economics literature. In any case, such exercises typically
lead one away from a simple linear model into the realm of non-linear models.

12

when the endogenous binary variable becomes rare, the linear model specification in the
first-stage could break down, resulting in a biased estimation of second-stage parameters
in the 2SLS approach. These biases could then compound biases from misfit of the linear
model to rare outcomes in the second-stage.

3. SIMULATIONS
We consider the simplest case where we have a binary outcome (yi), a binary treatment (di),
three binary controls (wi) and a binary instrument (zi). We chose three binary controls so
that the residuals from the first stage regression have at least thirty unique values in their
support. The central questions we try to answer with these simulations are: Can linear
approximation (2SLS) provide consistent estimates of the LATE for a binary outcome/binary
endogenous variable model? What form of residuals are most suited to a correctly
specified nonlinear 2SRI (Probit-Probit) approach? How do the results change if outcomes
(yi) and/or treatment (di) become rare?
The data generating processes (DGPs) are described below (subscripts i are suppressed for
clarity).
3.1 Exposure (treatment) DGP
d* = Œ±0 + Œ±1Œá w1 + Œ±2Œá w2 + Œ±3Œá w3 + Œ±ZŒá z + (Œ±UŒá wU ‚Äì œâ) ,

( 13 )

where (Œ±1, Œ±2, Œ±3) = (0.5, 1, 2), Œ±U = 1, Œ±Z = 1. Observed variables w1, w2, w3 and z are all
binary variables with mean equal to 0.5, generated by dichotomizing standard normal
variables around the value of 0. Together, (Œ±UŒá wU ‚Äì œâ) represents the empirical error term
for the treatment model and consists of the binary unobserved confounder, wU, which is
also based on dichotomizing a Normal (0,1), and the continuous model disturbance term, œâ
~ Normal(0,1). Observed treatment, d, is derived from the index function (d* > 0) and Pr(d)
= ÔÅÜ( (Œ±0 + 2.25)/‚àö3.5625)). We vary the model intercept, Œ±0, to take on values of -2, -1.25, 0.3, 0.5, and 1.5 which correspond to Pr(d) = 0.55, 0.70, 0.85, 0.93, and 0.995 respectively.
3.2 Outcomes DGP
y* = Œ≤0 + Œ≤ DŒá d + Œ≤ 1Œá w1 + Œ≤ 2Œá w2 + Œ≤ 3Œá w3 + (Œ≤UŒá wU ‚Äì Œµ)

( 14 )

13

Together (Œ≤UŒá wU ‚Äì Œµ) represents the empirical error term, u, from the theoretical outcomes
model under Section 2. Across all simulation models, true values of coefficients (Œ≤ 1, Œ≤ 2, Œ≤3)
were set to (1,1,1), the coefficient for the unmeasured confounder, Œ≤U, was set to 2, and
coefficient on treatment, Œ≤D, was set to 1. The model disturbance term Œµ ~ Normal(0,1) and
Pr(y|d) = ÔÅÜ( (Œ≤ 0 + Œ≤ DŒá d + 1.5)/‚àö5.75)). We vary Œ≤ 0 across simulations to take on values of -2,
0.5, 1.5, and 2.5 which correspond to Pr(y) = 0.51, 0.82, 0.93 and 0.96 respectively.

3.3 Target parameters
The primary target parameters were the ATE and the LATE. True values for the ATE and
LATE concepts were calculated in each simulation as:
ATE = E(y|d=1) - E(y|d=0) = ÔÅÜ( (Œ≤ 0 + 2.5)/‚àö5.75)) - ÔÅÜ( (Œ≤ 0 + 1.5)/‚àö5.75))

( 15 )

LATE = Ew{[E(y|z=1, w) ‚Äì E(y|z=0, w)] /[E(d|z=1, w) ‚Äì E(d|z=0, w)]}

( 16 )

where w = (w1, w2, w3, wu). The true value of the LATE parameter was simulated based on
100 samples of 1 million observations each.
3.4 Simulations
Estimates were generated using Monte-Carlo simulation methods, using 1,000 samples of
50,000 observations each to mitigate finite sample issues and also to align our simulation
with our empirical example. For each of the 1,000 simulated samples, 500 bootstrap resamples were drawn and used to calculate standard error and coverage values. Percent
bias was calculated as (‚àÜÃÇùëò - LATE)*100/LATE or ( ‚àÜÃÇùëò - ATE)*100/ATE averaged over all
simulated samples, where ‚àÜÃÇùëò is the estimated treatment effect for sample k. The
coefficient of variation is based on the standard deviation of the mean estimates across the
1,000 Monte-Carlo samples divided by the average of the mean estimates from those
samples. Finally, coverage probabilities for LATE and ATE were determined by averaging I((
ÃÇ ùëò ) ‚â§ LATE ‚â§ (‚àÜÃÇùëò + 1.96*ùëÜùê∏
ÃÇ ùëò )) and I(( ‚àÜÃÇùëò ‚Äì 1.96*ùëÜùê∏
ÃÇ ùëò ) ‚â§ ATE ‚â§ (‚àÜÃÇùëò + 1.96*ùëÜùê∏
ÃÇ ùëò )),
‚àÜÃÇùëò ‚Äì 1.96*ùëÜùê∏
ÃÇ ùëò is the
respectively, across all 1,000 samples, where I() is an indicator function and ùëÜùê∏
sample-specific standard error obtained via bootstrap.
Simulations were repeated using a sample size of 5,000 to magnify any finite sample
issues, and those results are presented in the appendix.

14

3.5 Estimators
We compared the following estimators:
1) IV regression with LPM (2SLS)
2) Probit-Probit 2SRI with
a) raw residuals as (di - dÃÇ),
b) standardized (Pearson) residuals given by (di - dÃÇi )/‚àö{(1- dÃÇi ) dÃÇi } ,
d

1‚àíd

c) deviance residuals, given by ‚àö2 {yi log (dÃÇi) + (1 ‚àí di )log (1‚àídÃÇi)} and
i

i

2 2

d) Anscombe residuals, (A(di ) ‚Äì A(dÃÇi ))/[A'(dÃÇi )‚àö{(d - dÃÇi ) dÃÇi } ], where A(di) = (B(di , 3 , 3) ‚Äì
1
2 2
B(dÃÇ, , ))/[‚àö{(1- dÃÇi ) dÃÇi } ]‚àí ‚ÅÑ6 and B() is a Beta Function.
3 3

‚Ä≤
e) Generalized residuals (Gourieroux et al. 1987): dÃÇi ‚àô(d - dÃÇi )/{(1- dÃÇi ) dÃÇi }

3) Bi-variate probit regression model, which is the MLE for the DGPs.

3.6 Results
Descriptive statistics for our DGPs are provided in Table 1. As expected, the true
mean average treatment effect (ATE) parameter values varied across scenarios varying the
intercept in the outcome models, Œ≤ 0, but not across scenarios varying the intercept in the
treatment models. LATE, however, varies with the intercepts in both the outcome and
treatment choice models. As outcomes become rare, following an underlying probit model,
both ATE and LATE decrease.
Simulation results are presented in Tables 2 and 3. Table 2 reports percent bias, the
coefficient of variation, and coverage probabilities on the LATE. We find that 2SLS always
provides consistent estimates of LATE, irrespective of the treatment rarity or outcomes
rarity. This indicates that 2SLS can consistently estimate the LATE effect even if the linear
probability model misfits the data and produces out of range predictions. Results do not

15

show any major drop in coverage probabilities for LATE across simulation design points.
Estimates from nonlinear 2SRI and bi-variate probit were generally biased for the LATE.
Table 3 reports percent bias, the coefficient of variation and coverage probabilities
on the ATE. As expected, given the DGPs, bi-variate probit always produced the least biased
estimates of the ATE. Also as expected, 2SLS produced biased estimates of ATE, especially
as the ATE and LATE became increasingly distinct in value with rarer treatment and
outcome. Results showed that all of the 2SRI estimators produced substantially larger
biases (and poor coverage probabilities) than bi-variate probit in estimating ATE. This
highlights the difficulty of estimating the ATE through extrapolation using the first-stage
residuals. Among the residual inclusion approaches, 2SRI with generalized residual
appeared to have the least bias in estimating ATE in most cases. However, the
corresponding coverage probabilities were low.
One interesting observation was that, for rare outcomes (such as those below 5%),
2SRI with Anscombe residuals produced the least bias in estimating ATE, with coverage
probabilities close to 95% in each case. The coverage probabilities did not deteriorate when
treatment also became rare. This may indicate that the Anscombe transformation of the
first-stage residuals are helping to approximate better the distribution of ui|vi where the
outcomes are rare and, therefore, abetting the extrapolation for the counterfactuals.
Results for patterns of bias with 2SLS and 2SRI held similar for the simulations with
a sample size of 5000 (Appendix Tables A2 and A3).

4. EMPIRICAL EXAMPLE
To illustrate the potential impact of the estimation method on empirical results, we
use the case of long-term care insurance (LTCI) and its impact on long-term care (LTC)
utilization. This issue has been studied by Konetzka, He, Guo and Nyman (2014) and Coe,
Goda and Van Houtven (2015). This application is fitting to illustrate the concepts
examined in the simulation models, as it is characterized by: 1) a relatively low E(Y) -- few
elderly hold long-term care insurance; 2) an empirically strong and widely accepted
instrumental variable ‚Äì state tax policies that reduce the cost of insurance influence LTCI
holding; and 3) multiple outcomes, at varying means Pr(Y).
4.1 Data

16

Three main data sources were used, following Coe, Goda and Van Houtven (2015): (1)
the Health and Retirement Study (HRS) (including RAND versions)
(http://hrsonline.isr.umich.edu/); (2) the HRS restricted geographic identifiers (HRS/G), in
order to match the individual to the state of residence, and (3) state-level tax subsidy data
for the purchase and holding of state-approved LTCI policies (GS Goda, 2011).
Data from ten waves of the HRS (1996-2010), a publicly available, bi-annual survey of
the near elderly in the U.S. were used.4 Respondents were ages 50 and older when they
initially entered the sample, and many respondents are observed long enough to have
used some type of long-term care. To increase the relevance of the instrumental variable
used for analysis ‚Äì the state tax subsidy ‚Äì the sample was limited to individuals who report
filing taxes and individuals in the top half of the income distribution in our sample. The
sample size consisted of 46,639 individual-wave observations. The Cross-Wave Geographic
Information (State) file matches respondents to their state of residence, which is then
matched to hand-collected data from individual state income tax return forms from 19962010 that describe tax subsidy programs for private long-term care insurance.
4.2 Measures and Descriptive Statistics
Five binary outcome measures were created; the measures had varying means to
illustrate the bias due to the estimation methods. Each outcome measure is created from
HRS data one wave (approximately two years) ahead of the data used to create explanatory
measures described below. Descriptive statistics for the data are shown in Table 3.
Informal Helper: Defining informal care in the HRS requires an algorithm based on
several variables. The process first identifies whether the person received care for specific
IADLS and ADLS and then uses information from relationship codes measured in the
helper file to determine whether the care was from a child, a friend or another relative to
ensure that the care recipient was not paid. We create 3 variables based on who provided
the informal care: 60 percent of the sample receives informal care from any person; 43
percent receive informal care from a child; 16.5 percent receive care from other relatives.
Home Health care: The formal home health care variables are: "Since the previous
interview, has any medically-trained person come to your home to help you, yourself?" In
2000, the HRS clarified that medically-trained persons include professional nurses, visiting
4

Earlier waves of the survey are omitted because of the lower quality information on the LTCI question (Finkelstein
and McGarry, 2006) and state information is not yet available for later waves.

17

nurse's aides, physical or occupational therapists, chemotherapists, and respiratory oxygen
therapists, which may represent an expansion of the definition of home health care. 6.8
percent received home health care.
Nursing home care: The HRS asks: ‚ÄúSince (Previous Wave Interview Month-Year/In the
last two years), have you been a patient overnight in a nursing home, convalescent home,
or other long-term health care facility?‚Äù For individuals who died between waves, nursing
home use was measured from data in the HRS exit interviews. 2.3 percent received nursing
home care.
LTCI (mean=0.157): Starting in the 1996 wave, respondents were asked to respond
yes or no to the following question: ‚ÄúNot including government programs, do you now have
any long term care insurance which specifically covers nursing home care for a year or
more or any part of personal or medical care in your home?‚Äù. LTCI status is defined as
having LTCI in year t, based on the recorded response to this question; 15.7 percent of
individual-waves had long-term care insurance.
State Tax Subsidy (an instrument for LTCI): Following the literature, a binary variable
indicating whether a state has a tax subsidy available in a particular year was created to be
used as an instrument for LCTI. The state tax subsidy indicated any subsidy, regardless of
the form of the subsidy (i.e., credit or a deduction), the fraction of premiums eligible,
monetary caps on the value of the subsidy, income limits, or whether the state subsidy was
available in addition to the federal subsidy (GS Goda, 2011; Konetzka et al. 2014; Coe, Goda
and Van Houtven 2015). The availability of a state tax subsidy varied considerably over
time and across states; while only three states had tax incentives for LTCI in 1996, a total of
24 states plus the District of Columbia had adopted a subsidy by 2008. Prior literature has
provided evidence that the state tax subsidy is empirically important in whether someone
holds a LTCI policy and meets essential criteria for use as an instrumental variable in this
context. In the first stage regression, the estimated coefficient on the binary state tax
subsidy variable suggested that individuals in states with subsidies are about three
percentage points more likely to own LTCI (F-stat: 65.93, p<0.001).
Individual-level control variables. Control variables in the models included binary
variables indicating respondent‚Äôs marital status, sex, number of children, retirement status,
education, income, race, ethnicity, health status (fair or poor self-reported health and the
presence of any limitations in the activities of daily living (ADLs)), and age fixed effects.

18

Fixed-effects. All models include the year and state fixed-effects. The year fixedeffects account for time trends in the data while the state fixed-effects account for nontime-varying differences across states. The inclusion of state fixed-effects suggests that the
empirical models identify the effect of LTCI coverage on the outcome for individuals whose
LTCI coverage was sensitive to within-state differences in the state tax policy.
Analyses included the use of all estimators represented in the simulations models
described in the previous section. Each estimator was used to estimate the effect of longterm care insurance on each of the five outcomes described above, using the binary state
tax subsidy variable as an instrumental variable. For each estimator, estimates from 500
clustered bootstrap samples were used to compute standard errors for the marginal effect
in each case.

4.3 Results
The simulation results indicated that 2SLS should produce consistent estimates of
LATEs, regardless of treatment or outcome rarity. Conversely, results suggested 2SRI
models were likely to produce bias in estimating average treatment effects on outcomes
(ATE or LATE), with generalized residuals estimator (2SRI-Gres) producing the least bias. For
very rare outcome, such as nursing home care and home health care in our empirical
application, 2SRI with Anscombe residual (2SRI-ares) may produce estimates close to the
unbiased estimates of ATE.
Table 4 provides summary statistics for outcomes and other variables used in the
empirical models. The marginal effects and their bootstrapped standard errors are shown
in Table 5.
The 2SLS-based consistent LATE estimates for LTCI were -0.302 (Informal care from
any source), -0.329 (Informal care from child), 0.161 (Informal care from relatives), -0.252
(home health care), and 0.087 (Any nursing home care). The interpretation of LATE always
refers to the marginal individuals. For example, in the model predicting informal care from
any source, the LATE estimate suggests that LTCI decreases the use of informal care from
any source by 30 percentage points among people who are moved to acquire LTCI due to
the subsidy. Sometimes, LATE can provide treatment effects estimates that are difficult to
interpret, and may even be considered nonsensical, even when the IV is policy-driven. For
example, assuming that access to LTCI would increase receipt of formal care, which will act

19

as a substitute for all forms of informal care, the effect of LTCI on Informal care from any
source would perhaps not be expected to be smaller than the effect on Informal care from
child, yet that is what LATE suggests. Similarly, it is difficult to envision how the effect from
having LTCI, for those who have insurance due to state subsidies, increases informal care
from a relative; though this LATE estimate does not reach statistical significance. One may
invoke complicated stories about complementarity between formal care and informal care
from relatives and particularities about the generosity of LTCI for those who have it due to
state subsidies, to explain these result. Then again, the real world is full such complexities
and taking the time to disentangle such nuanced relationships may be considered
worthwhile. Note that the LATEs for different outcomes belong to the same marginal
group of patients who are influenced by this specific IV.
Treatment effect estimates produced from the 2SRI models are often quite different
from the 2SLS-based LATE estimates. This was expected. The 2SRI-Gres estimates of ATE
for LTCI are -0.268 (Informal care from any source), -0.179 (Informal care from child), -0.111
(Informal care from relatives), -0.077 (home health care) and 0.023 (Any nursing home
care). Taken at face value, these estimates did not have the contextual inconsistencies, as it
relates to our a priori theory about the relationships under study, which were seen in LATE
estimates. The 2SRI estimates were also quite similar to those produced by the Bi-Probit
model, especially when outcomes mean was close to 0.50. It is quite plausible that the
underlying distribution of outcomes is well approximated by a normal distribution when
the binary outcome mean is close to 0.50, and hence, for these outcomes, the bi-probit
model is likely to produce consistent estimates of ATE.5 For rarer outcomes, the bi-probit
estimates and the 2SRI-gres estimates differ and it is not clear if any of those estimates are
unbiased estimates of ATE.
For any nursing home care, which is the rarest outcome, 2SRI-ares (with Anscombe
residuals) estimates of ATE are close to being unbiased, according to our simulations.
Although this point estimate of 0.038 differs from that of Bi-probit (= 0.023), neither reach
statistical significance. Hence, it is reasonable to conclude that the overall average effect of
LTCI in the entire population does not significantly affect any nursing home care.

5

Note that in contrast to our simulations, where we generate all outcomes under the normal distribution and found
the BVP perform better for rare outcomes, here we are suggesting that when the outcomes mean is around 50% its
underlying data-generating process is more likely to be normal.

20

5. CONCLUSIONS
The economics literature is teeming with applications where linear probability
models are used for binary outcomes. In case of instrumental variables methods, both the
binary treatment (in 1st stage) and the binary outcome (in 2nd stage) are often modeled with
linear probability models with two-stage least squares (2SLS) estimators. In contrast, a
control function approach may be used with non-linear models (e.g., probit or logit applied
to first and/or second stage models) where the estimated residuals from the first stage are
used as an additional covariate in the second stage. However, the residual inclusion
approach does not identify a treatment effect non-parametrically. Instead, it relies on
extrapolation for the counterfactual outcomes conditional of the level of a residual using
the functional form used. The proper characterization of these residuals is thought to be
important to carry out such extrapolations. This research considered the case where a
local average treatment effect (LATE) parameter is non-parametrically identified using a
binary instrument in the presence of all binary covariates. Extensive simulations that varied
the rarity of both the outcome and treatment were performed to answer questions of
whether 2SLS or 2SRI methods with different forms of residuals has the least bias in
estimating the LATE or the ATE parameters.
Results show that the 2SLS method with binary IV, applied to a binary endogenous
treatment and a binary outcome, produces consistent estimates of LATE across the entire
range of rarity for either treatment or the outcome. The rarity of either does not affect the
coverage probabilities of these estimators. In contrast, the 2SRI approach with any
residuals studied was a biased estimator for LATE. However, in principle, the 2SRI
estimators are designed to estimate the ATE parameter. Still, results showed that 2SRI does
not appear dependable for producing unbiased estimates of ATE. Rather, there were
varying levels of bias associated with 2SRI estimates of ATE. Among the residual forms, 2SRI
with generalized residuals appeared to produce the least biased estimates of the ATE. For
very rare outcomes (<5%) 2SRI with Anscombe residual generated the least bias in
estimating ATE. We conjecture that the symmetric transformation of these residuals may
be leading to better extrapolation properties of the 2SRI estimators. However, whether
these findings represent a general operating characteristic of 2SRI or are unique to our
simulation settings is not known.
Results from this study conform to the simulation results of Chapman and Brooks
(2016), who carry out similar simulations to find that 2SLS produced the consistent
estimates for the LATE while 2SRI does not reliably estimate either the ATE or LATE.

21

However, their study did not vary rarity of treatment or outcome from approximately 0.5 or
examine alternative forms of 2SRI residuals. The results of this study provide additional
evidence showing how 2SLS are consistent estimators of LATE over a wider range of means
for binary outcomes and binary treatments.
We hope that this work will help the applied researcher to cautiously approach and
interpret the results generated from IV estimation in models with binary treatment, binary
outcome, and binary instrumental variable. Careful interpretation of treatment effects that
are identified and being estimated, as well as the potential for bias arising from
methodologic decisions, are key factors to consider in conducting these analyses and
responsibly reporting the results from them. While estimating the LATE may be
straightforward given a valid instrument, the interpretation of LATEs is often nuanced and
may heighten the potential for unintentionally misleading or erroneous inferences and
conclusions. On the other hand, interpreting population mean treatment effect parameters
such as the ATE is straight-forward but estimating them is often problematic and
potentially infeasible, as doing so demands either richer data or a slew of statistical
assumptions that may not be met. Moreover, under settings of essential heterogeneity in
treatment effectiveness, the potential usefulness of a population-wide average effect may
be limited and more nuanced parameters are required for practical impact. It‚Äôs important
that researchers understand precisely the assumptions underlying identification of
alternative treatment effect concepts and the related theory to support an approach for
estimating them. We are hopeful that our results and discussions can help untangle these
challenges.

22

Appendix

23

Table A1: Simulations results (N=5,000) for Local Average Treatment Effects (LATEs) - %Bias (Coeff. Var.) {Coverage Pr}
E(Y)

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

0.50~0.60

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres

170 [.02] {0}
-1 [.27] {.94}
-47 [.59] {.67}
11 [.27] {.92}
-103 [-9.25] {.14}
-88 [2.74] {.24}
-46 [.56] {.65}
-22 [.31] {.83}
233 [.04] {0}
-3 [.52] {.95}
-3 [.47] {.95}
74 [.19] {.39}
-75 [2.27] {.73}
-52 [1.07] {.83}
-4 [.45] {.96}
-5 [.4] {.94}
322 [.05] {0}
-2 [.96] {.93}
58 [.44] {.82}
134 [.19] {.15}
-27 [1.35] {.94}
0 [.86] {.94}
52 [.43] {.81}
24 [.54] {.92}
492 [.07] {0}
-3 [2] {.94}
158 [.47] {.83}
236 [.29] {.32}
56 [1.15] {.95}
86 [.82] {.95}
148 [.47] {.81}
26 [2.05] {.85}

182 [.03] {0}
-2 [.35] {.95}
-31 [.5] {.83}
32 [.29] {.82}
-99 [38.24] {.28}
-81 [1.98] {.41}
-32 [.49] {.82}
-16 [.34] {.89}
185 [.04] {0}
-1 [.37] {.95}
-36 [.54] {.75}
69 [.17] {.32}
-95 [7.59] {.26}
-68 [1.09] {.49}
-31 [.47] {.8}
-31 [.4] {.74}
232 [.05] {0}
0 [.61] {.93}
-9 [.54] {.92}
97 [.19] {.19}
-77 [2.57] {.69}
-45 [.96] {.83}
-8 [.51] {.91}
-21 [.51] {.88}
322 [.07] {0}
-4 [1.1] {.94}
34 [.53] {.99}
144 [.21] {.17}
-52 [2.02] {.98}
-14 [.91] {1}
25 [.52] {.99}
-7 [.78] {.97}

242 [.03] {0}
-4 [.71] {.96}
44 [.37] {.86}
96 [.33] {.59}
-47 [1.25] {.82}
-32 [.94] {.86}
24 [.44] {.91}
9 [.49] {.93}
155 [.04] {0}
-1 [.36] {.94}
-70 [1.01] {.33}
57 [.18] {.41}
-103 [-9.52] {.09}
-76 [1.15] {.23}
-51 [.58] {.5}
-47 [.45] {.43}
165 [.05] {0}
1 [.46] {.93}
-69 [1.18] {.41}
64 [.2] {.43}
-97 [10.3] {.19}
-66 [.98] {.4}
-47 [.63] {.57}
-50 [.57] {.45}
202 [.08] {0}
-2 [.66] {.94}
-61 [1.22] {.64}
84 [.24] {.56}
-92 [5.92] {.45}
-55 [.96] {.64}
-38 [.7] {.73}
-50 [.73] {.64}

381 [.03] {0}
-11 [2.08] {.96}
208 [.35] {.45}
215 [.42] {.52}
131 [.58] {.76}
123 [.59] {.79}
155 [.46] {.67}
54 [1.06] {.87}
160 [.04] {0}
-2 [.53] {.95}
-78 [1.71] {.42}
61 [.22] {.52}
-94 [5.58] {.22}
-70 [1.18] {.44}
-59 [.87] {.51}
-52 [.62] {.47}
143 [.06] {0}
0 [.52] {.93}
-94 [4.73] {.22}
43 [.21] {.66}
-98 [12.3] {.14}
-72 [1.08] {.34}
-66 [.9] {.34}
-62 [.71] {.29}
150 [.09] {0}
0 [.58] {.95}
-101 [-37.55] {.25}
41 [.26] {.81}
-98 [15.37] {.19}
-70 [.98] {.39}
-67 [.89] {.43}
-68 [.74] {.34}

845 [.04] {0}
-61 [27.76] {.97}
476 [.85] {.58}
428 [.99] {.53}
534 [.75] {.5}
488 [.81] {.54}
399 [.98] {.61}
297 [1.83] {.47}
226 [.06] {0}
-7 [1.74] {.96}
-44 [1.71] {.79}
106 [.34] {.55}
-33 [1.26] {.82}
-18 [1.02] {.84}
-38 [1.35] {.79}
-33 [1.11] {.8}
160 [.08] {0}
-5 [1.15] {.95}
-83 [3.52] {.53}
51 [.29] {.77}
-77 [2.09] {.51}
-55 [1.13] {.64}
-67 [1.47] {.57}
-60 [1.09] {.55}
130 [.12] {0}
-1 [.9] {.95}
-92 [6.21] {.51}
19 [.34] {.92}
-87 [2.92] {.41}
-65 [1.27] {.53}
-74 [1.64] {.48}
-70 [1.25] {.46}

Bi.Probit
0.80 ~0.90

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

0.9 ~ 0.95

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

0.95~0.98

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

2SRI ‚Äì sres: 2SRI with standardized residuals; 2SRI ‚Äì dres: 2SRI with deviance residuals; 2SRI ‚Äì ares: 2SRI with Anscombe residuals;
2SRI-gres: 2SRI with generalized residuals; Shaded cells highlight estimator with lowest percentage bias.
24

Table A2: Simulations results (N=5,000) comparing to Average Treatment Effects (ATEs) - %Bias (Coeff. Var.) {Coverage Pr}
E(Y)

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

0.50~0.60

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres

248 [.02] {0}
28 [.27] {.88}
-32 [.59] {.86}
44 [.27] {.81}
-104 [-9.25] {.3}
-85 [2.74] {.42}
-31 [.56] {.86}
1 [.31] {.93}
244 [.04] {0}
0 [.52] {.95}
0 [.47] {.95}
79 [.19] {.36}
-74 [2.27] {.74}
-50 [1.07] {.83}
-1 [.45] {.97}
-2 [.4] {.94}
226 [.05] {0}
-25 [.96] {.91}
22 [.44] {.9}
81 [.19] {.3}
-44 [1.35] {.93}
-23 [.86] {.93}
18 [.43] {.92}
-4 [.54] {.95}
202 [.07] {0}
-50 [2] {.89}
32 [.47] {.96}
72 [.29] {.79}
-20 [1.15] {.96}
-5 [.82] {.96}
27 [.47] {.95}
-36 [2.05] {.94}

237 [.03] {0}
18 [.35] {.91}
-17 [.5] {.9}
58 [.29] {.68}
-99 [38.24] {.39}
-78 [1.98] {.53}
-18 [.49] {.90}
0 [.34] {.93}
314 [.04] {0}
43 [.37] {.84}
-7 [.54] {.95}
145 [.17] {.07}
-93 [7.59] {.53}
-53 [1.09] {.78}
1 [.47] {.94}
0 [.4] {.95}
327 [.05] {0}
28 [.61] {.91}
18 [.54] {.94}
154 [.19] {.05}
-70 [2.57] {.81}
-29 [.96] {.91}
18 [.51] {.94}
2 [.51] {.94}
326 [.07] {0}
-3 [1.1] {.94}
35 [.53] {.99}
146 [.21] {.17}
-52 [2.02] {.98}
-14 [.91] {1}
26 [.52] {.99}
-6 [.78] {.97}

210 [.03] {0}
-13 [.71] {.94}
31 [.37] {.89}
78 [.33] {.64}
-52 [1.25] {.8}
-38 [.94] {.84}
12 [.44] {.91}
-1 [.49] {.93}
407 [.04] {0}
97 [.36] {.71}
-40 [1.01] {.81}
213 [.18] {.02}
-105 [-9.52] {.39}
-51 [1.15] {.75}
-3 [.58] {.92}
4 [.45] {.95}
482 [.05] {0}
121 [.46] {.68}
-32 [1.18] {.84}
260 [.2] {0}
-93 [10.3] {.59}
-25 [.98] {.87}
17 [.63] {.91}
10 [.57] {.93}
546 [.08] {0}
110 [.66] {.86}
-16 [1.22] {.95}
295 [.24] {.03}
-83 [5.92] {.8}
-4 [.96] {.96}
32 [.7] {.98}
7 [.73] {.94}

187 [.03] {0}
-47 [2.08] {.94}
84 [.35] {.66}
88 [.42] {.68}
38 [.58] {.85}
33 [.59] {.86}
52 [.46] {.81}
-8 [1.06] {.86}
488 [.04] {0}
121 [.53] {.82}
-49 [1.71] {.77}
262 [.22] {.07}
-87 [5.58] {.59}
-32 [1.18] {.81}
-8 [.87] {.88}
9 [.62] {.91}
648 [.06] {0}
208 [.52] {.65}
-80 [4.73] {.64}
340 [.21] {.02}
-93 [12.3] {.57}
-14 [1.08] {.86}
3 [.9] {.9}
16 [.71] {.91}
815 [.09] {0}
265 [.58] {.7}
-103 [-37.55] {.71}
417 [.26] {.03}
-94 [15.37] {.71}
10 [.98] {.93}
21 [.89] {.94}
18 [.74] {.93}

163 [.04] {0}
-89 [27.76] {.96}
61 [.85] {.71}
47 [.99] {.67}
77 [.75] {.69}
64 [.81] {.69}
39 [.98] {.7}
11 [1.83] {.5}
582 [.06] {0}
95 [1.74] {.93}
17 [1.71] {.9}
331 [.34] {.31}
40 [1.26] {.89}
71 [1.02] {.89}
29 [1.35] {.88}
41 [1.11] {.9}
883 [.08] {0}
260 [1.15] {.85}
-37 [3.52] {.86}
472 [.29] {.19}
-13 [2.09] {.85}
71 [1.13] {.93}
27 [1.47] {.9}
52 [1.09] {.93}
1277 [.12] {0}
491 [.9] {.79}
-50 [6.21] {.79}
612 [.34] {.24}
-25 [2.92] {.83}
109 [1.27] {.93}
55 [1.64] {.91}
78 [1.25] {.93}

Bi.Probit
0.80 ~0.90

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

0.9 ~ 0.95

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

0.95~0.98

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

2SRI ‚Äì sres: 2SRI with standardized residuals; 2SRI ‚Äì dres: 2SRI with deviance residuals; 2SRI ‚Äì ares: 2SRI with Anscombe residuals;
2SRI-gres: 2SRI with generalized residuals; Shaded cells highlight estimator with lowest percentage bias.
25

REFERENCES
ABADIE, A. Semiparametric Instrumental Variable Estimation of Treatment Response
Models." Journal of Econometrics 2009; 113:231-63.
ABREVAYA, J., HAUSMAN, J.A., and S. KHAN S. Testing for casual effects in a generalized
regression model with endogenous regressors. Economterica 2010; 78(6): 2043-2061.
BASU, A., HECKMAN, J.J., NAVARRO-LOZANO, S., and S. URZUA. Use of instrumental
variables in the presence of heterogeneity and self-selection: An application to
treatments of breast cancer patients. Health Economics 2007; 16(11): 1133 -1157.
BHATTACHARYA J, GOLDMAN D, McCAFFREY D. Estimating probit models with self-selected
treatments. Statistics in Medicine 2006; 25(3): 389-413.
BLUNDELL, R. W. and POWELL, J. L. Endogeneity in Nonparametric and Semiparametric
Regression Models, in M. Dewatripont, L. P. Hansen and S. J. Turnovsky (eds.)
Advances in Economics and Econometrics: Theory and Applications, Eighth World
Congress, Vol. II (Cambridge: Cambridge University Press), 2003.
BLUNDELL, R. W. and POWELL, J. L. Endogeneity in semiparametric binary response
models. Review of Economic Studies 2004; 71, 655-679.
BLUNDELL, R.W. and SMITH, R. J. An Exogeneity Test for a Simultaneous Tobit Model,
Econometrica 1986; 54, 679‚Äì685.
BLUNDELL, R. W. and SMITH, R. J. Estimation in a Class of Simultaneous Equation Limited
Dependent Variable Models. Review of Economic Studies 1989; 56, 37‚Äì58.
CHAPMAN CG, BROOKS JM. Treatment effect estimation using nonlinear two-stage
instrumental variable estimators: Another cautionary note. Health Services Research
2016; 51(6): 2375-2394.
CHIBURIS, R. Semiparametric Bounds on Treatment Effects. Journal of Econometrics 2010;
159(2):267-275.
CHIBURIS, R., DAS, J and M. LOKSHIN. A practical comparison of the bivariate probit and
linear IV estimators. Economic Letters 2012; 117(3): 762-766.
COE, N.B., GODA G.S., AND C.H. VAN HOUTVEN. Long-term Care Insurance and Family
Behavior. NBER Working paper w21483, 2015.

26

FINKELSTEIN, AN and K MCGARRY. Multiple Dimensions of Private Information: Evidence
from the Long-Term Care Insurance Market. American Economic Review 2006; 96(4),
938-58.
GARRIDO, M.M., DEB P., BURGESS J.F., PENROD J.D. Choosing models for cost analyses:
Issues of nonlinearity and endogeneity. Health Services Research 2012; 47(6): 23772397.
GODA, GS. "The Impact of State Tax Subsidies for Private Long-Term Care Insurance on
Coverage and Medicaid Expenditures." Journal of Public Economics 2011; 95(7-8), 74457.
GOURIEROUX CA, MONFORT, TROGNON A. Generalised residuals. Journal of Econometrics
1987; 34: 5-32
HECKMAN, J. J. ‚ÄúDummy Endogenous Variable in a Simultaneous Equations System‚Äù,
Econometrica 1978; 46, 931‚Äì959.
HECKMAN JJ. Instrumental Variables: A study of implicit behavioral assumptions used in
making program evaluations. Journal of Human Resources 1997; 32 (3): 441-462.
HECKMAN JJ, URZUA S, VYTLACIL E. Understanding instrumental variables in models with
essential heterogeneity. Review of Economics and Statistics 2006; 88(3): 389-432.
HORRACE WC, OAXACA RL. Results on the bias and inconsistency of ordinary least squares
for the linear probability model. Economic Letters 2006; 321-327.
IMBENS G, ANGRIST J. Identification and estimation of local average treatment effects.
Econometrica 1994; 62(2): 467-475.
KONETZKA, RT, D HE, J GUO and J NYMAN. 2014. ‚ÄúMoral Hazard and Long-Term Care
Insurance.‚Äù Working paper available:
http://business.illinois.edu/nmiller/mhec/Konetzka.pdf
MCCARTHY, IM AND R. TCHERNIS. On the Estimation of Selection Models when
Participation is Endogenous and Misclassied. In D. Drukker (Ed.) Advances in
Econometrics, Missing-Data Methods: Cross-sectional methods and Applications 2011;
27:179-207. London: Emerald Group Publishing.
NEWHOUSE J, MCCLELLAN MB. Econometrics in Outcomes Research: The Use of
Instrumental Variables. Annual Review of Public Health 1998; 19:17-34.
SHAIKH, A.M. and E.J. Vytlacil. Partial identification in triangular systems of equation with
binary dependent variables. Econometrica 2011; 79(3): 949-955.

27

TELSER, L. G. Iterative Estimation of a Set of Linear Regression Equations. Journal of the
American Statistical Association 1964; 59, 845‚Äì862.
TERZA JV, BRADFORD WD, DISMUKE CE. The use of linear instrumental variables methods
in Health Services Research and Health Economics: A cautionary note. Health
Services Research 2007; 43(3): 1102-1120.
TERZA JV, BASU A, RATHOUZ PJ. Two-stage residual inclusion estimation: Addressing
endogeneity in health econometric modeling. Journal of Health Economics 2008;
27(3):531-543.
WOOLDRIDGE J. Control function methods in applied econometrics. The Journal of Human
Resource 2015; 50(2): 420-445.

28

.4

E(y)

.6

.8

1

Figure 1: Illustration of residual inclusion approach for binary treatment variable.

<--- d = 0 d = 1 --->

0

.2

Residuals for d=1
Residuals for d=0
Fitted lines
Extrapolated lines
-1

-.5

0
Residuals

.5

1

29

Table 1: Descriptive statistics for alternative data generating processes.
Outcomes DGP
(Œ≤0)
-2

-2

-1.25

Exposure DGP (Œ±0)
-0.3

0.5

1.5

Pr(D) = 0.55
Pr(D) = 0.70
Pr(D) = 0.85
Pr(D) = 0.93
Pr(D) = 0.995
E(Y) = 0.51
E(Y) = 0.54
E(Y) = 0.57
E(Y) = 0.57
E(Y) = 0.58
ATE = 0.165
ATE = 0.165
ATE = 0.165
ATE = 0.165
ATE = 0.165
TT= 0.168
TT= 0.176
TT= 0.176
TT= 0.172
TT= 0.170
TUT =0.160
TUT =0.140
TUT =0.101
TUT =0.071
TUT =0.031
LATE = 0.212
LATE = 0.198
LATE = 0.150
LATE = 0.098
LATE = 0.046
0.5
Pr(D) = 0.55
Pr(D) = 0.70
Pr(D) = 0.85
Pr(D) = 0.93
Pr(D) = 0.995
E(Y) = 0.82
E(Y) = 0.84
E(Y) = 0.86
E(Y) = 0.87
E(Y) = 0.89
ATE = 0.097
ATE = 0.097
ATE = 0.097
ATE = 0.097
ATE = 0.097
TT= 0.044
TT= 0.060
TT= 0.078
TT= 0.088
TT=0.93
TUT =0.162
TUT =0.181
TUT =0.202
TUT =0.201
TUT =0.172
LATE = 0.100
LATE = 0.141
LATE = 0.192
LATE = 0.218
LATE = 0.203
1.5
Pr(D) = 0.55
Pr(D) = 0.70
Pr(D) = 0.85
Pr(D) = 0.93
Pr(D) = 0.995
E(Y) = 0.93
E(Y) = 0.93
E(Y) = 0.93
E(Y) = 0.95
E(Y) = 0.95
ATE = 0.058
ATE = 0.058
ATE = 0.058
ATE = 0.058
ATE = 0.058
TT=0.017
TT=0.025
TT=0.038
TT=0.047
TT=0.054
TUT =0.109
TUT =0.133
TUT =0.168
TUT =0.197
TUT =0.217
LATE = 0.045
LATE = 0.075
LATE = 0.127
LATE = 0.178
LATE =0.220
2.5
Pr(D) = 0.55
Pr(D) = 0.70
Pr(D) = 0.85
Pr(D) = 0.93
Pr(D) = 0.995
E(Y) = 0.96
E(Y) = 0.96
E(Y) = 0.96
E(Y) = 0.98
E(Y) = 0.98
ATE = 0.029
ATE = 0.029
ATE = 0.029
ATE = 0.029
ATE = 0.029
TT=0.005
TT=0.008
TT=0.014
TT=0.020
TT=0.023
TUT =0.059
TUT =0.077
TUT =0.110
TUT =0.144
TUT =0.185
LATE = 0.015
LATE = 0.029
LATE = 0.062
LATE = 0.107
LATE = 0.175
TT: Effect on the Treated; TUT: Effect on the Untreated; True values of TT and TUT are provided for information only

30

Table 2: Simulations results (N=50,000) for Local Average Treatment Effects (LATEs) - %Bias (Coeff. Var.) {Coverage Pr}
E(Y)

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

0.50~0.60

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

170 [.01] {0}
-1 [.08] {.96}
-49 [.19] {0}
12 [.08] {.75}
-106 [-1.45] {0}
-91 [1.07] {0}
-48 [.18] {0}
-23 [.1] {.17}

182 [.01] {0}
-1 [.1] {.96}
-33 [.16] {.17}
36 [.09] {.17}
-102 [-5.19] {0}
-84 [.68] {0}
-33 [.15] {.13}
-17 [.1] {.5}

242 [.01] {0}
-2 [.21] {.95}
42 [.12] {.34}
109 [.11] {0}
-50 [.42] {.36}
-34 [.3] {.62}
22 [.14] {.73}
9 [.15] {.92}

382 [.01] {0}
-5 [.59] {.94}
205 [.12] {0}
267 [.14] {0}
126 [.19] {.15}
120 [.19] {.18}
150 [.15] {.03}
63 [.3] {.75}

846 [.01] {0}
-30 [4.64] {.94}
774 [.15] {.01}
799 [.2] {.04}
834 [.12] {0}
775 [.15] {0}
656 [.22] {.05}
171 [1.57] {.84}

0.80 ~0.90

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

233 [.01] {0}
0 [.17] {.91}
-1 [.16] {.92}
75 [.06] {0}
-71 [.69] {.04}
-48 [.34] {.15}
-1 [.15] {.92}
-3 [.13] {.93}

185 [.01] {0}
0 [.13] {.92}
-38 [.19] {.09}
71 [.05] {0}
-97 [3.72] {0}
-68 [.39] {0}
-31 [.17] {.17}
-31 [.14] {.08}

156 [.01] {0}
0 [.12] {.92}
-75 [.38] {0}
63 [.06] {0}
-107 [-1.15] {0}
-79 [.42] {0}
-55 [.2] {0}
-50 [.15] {0}

161 [.01] {0}
0 [.17] {.93}
-86 [.8] {0}
72 [.08] {0}
-101 [-6.45] {0}
-74 [.42] {0}
-65 [.3] {0}
-56 [.19] {0}

228 [.02] {0}
-1 [.51] {.93}
-79 [1.38] {.25}
134 [.11] {0}
-59 [.65] {.38}
-35 [.45] {.67}
-62 [.69] {.35}
-51 [.44] {.33}

0.9 ~ 0.95

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

322 [.02] {0}
-1 [.29] {.94}
61 [.12] {.1}
134 [.06] {0}
-18 [.34] {.9}
7 [.23] {.91}
56 [.12] {.14}
29 [.16] {.66}

232 [.02] {0}
-1 [.18] {.95}
-12 [.16] {.82}
97 [.05] {0}
-78 [.77] {.01}
-47 [.28] {.11}
-11 [.15] {.83}
-22 [.15] {.48}

166 [.02] {0}
-1 [.13] {.95}
-76 [.41] {0}
68 [.06] {0}
-103 [-2.91] {0}
-71 [.32] {0}
-52 [.19] {0}
-54 [.17] {0}

144 [.02] {0}
-1 [.15] {.94}
-102 [-3.35] {0}
51 [.08] {0}
-105 [-1.29] {0}
-78 [.39] {0}
-73 [.31] {0}
-67 [.2] {0}

162 [.02] {0}
-2 [.31] {.96}
-108 [-1.19] {0}
63 [.11] {.02}
-96 [2.73] {0}
-68 [.49] {.04}
-84 [.8] {0}
-73 [.38] {0}

0.95~0.98

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

493 [.02] {0}
-2 [.6] {.95}
174 [.1] {0}
244 [.06] {0}
88 [.22] {.45}
111 [.17] {.16}
164 [.1] {0}
90 [.24] {.48}

324 [.02] {0}
-1 [.32] {.96}
32 [.14] {.62}
142 [.06] {0}
-43 [.44] {.63}
-11 [.23] {.94}
25 [.14] {.72}
-2 [.19] {.96}

203 [.02] {0}
-1 [.19] {.97}
-67 [.36] {0}
87 [.07] {0}
-95 [2.42] {0}
-60 [.29] {0}
-44 [.21] {.05}
-53 [.2] {0}

151 [.03] {0}
-2 [.17] {.97}
-108 [-.99] {0}
48 [.09] {.01}
-104 [-1.66] {0}
-76 [.32] {0}
-74 [.3] {0}
-73 [.22] {0}

133 [.04] {0}
-3 [.25] {.96}
-111 [-.33] {0}
30 [.12] {.4}
-102 [-2.92] {0}
-78 [.49] {0}
-89 [.82] {0}
-83 [.4] {0}

2SRI ‚Äì sres: 2SRI with standardized residuals; 2SRI ‚Äì dres: 2SRI with deviance residuals; 2SRI ‚Äì ares: 2SRI with Anscombe residuals;
2SRI-gres: 2SRI with generalized residuals; Shaded cells highlight estimator with lowest percentage bias.
31

Table 3: Simulations results (N=50,000) comparing to Average Treatment Effects (ATEs) - %Bias (Coeff. Var.) {Coverage Pr}
E(Y)

Estimators

Pr(D) = 0.55

Pr(D) = 0.70

Pr(D) = 0.85

Pr(D) = 0.93

Pr(D) = 0.995

0.50~0.60

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

248 [.01] {0}
28 [.08] {.28}
-34 [.19] {.28}
44 [.08] {.05}
-108 [-1.45] {0}
-88 [1.07] {0}
-33 [.18] {.3}
-1 [.1] {.95}

237 [.01] {0}
18 [.1] {.69}
-20 [.16] {.66}
63 [.09] {.01}
-103 [-5.19] {0}
-80 [.68] {0}
-20 [.15] {.63}
-1 [.1] {.97}

211 [.01] {0}
-11 [.21] {.92}
28 [.12] {.55}
90 [.11] {0}
-55 [.42] {.19}
-40 [.3] {.42}
11 [.14] {.88}
-1 [.15] {.95}

187 [.01] {0}
-43 [.59] {.78}
82 [.12] {.03}
119 [.14] {.02}
35 [.19] {.71}
31 [.19] {.74}
49 [.15] {.42}
-3 [.3] {.94}

164 [.01] {0}
-80 [4.64] {.86}
144 [.15] {.09}
151 [.2] {.18}
161 [.12] {.01}
144 [.15] {.05}
111 [.22] {.36}
-25 [1.57] {.85}

0.80 ~0.90

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

244 [.01] {0}
3 [.17] {.9}
2 [.16] {.9}
80 [.06] {0}
-71 [.69] {.04}
-47 [.34] {.22}
2 [.15] {.92}
0 [.13] {.94}

314 [.01] {0}
45 [.13] {.25}
-10 [.19] {.85}
149 [.05] {0}
-95 [3.72] {0}
-54 [.39] {.1}
0 [.17] {.91}
0 [.14] {.91}

407 [.01] {0}
98 [.12] {.01}
-49 [.38] {.25}
224 [.06] {0}
-114 [-1.15] {0}
-58 [.42] {.1}
-10 [.2] {.89}
0 [.15] {.93}

489 [.01] {0}
125 [.17] {.1}
-68 [.8] {.26}
289 [.08] {0}
-103 [-6.45] {.01}
-42 [.42] {.56}
-20 [.3] {.8}
0 [.19] {.94}

587 [.02] {0}
107 [.51] {.78}
-55 [1.38] {.72}
390 [.11] {0}
-13 [.65] {.89}
36 [.45] {.88}
-20 [.69] {.87}
2 [.44] {.93}

0.9 ~ 0.95

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

226 [.02] {0}
-24 [.29] {.79}
24 [.12] {.6}
81 [.06] {0}
-37 [.34] {.6}
-18 [.23] {.85}
21 [.12] {.67}
0 [.16] {.92}

327 [.02] {0}
27 [.18] {.76}
13 [.16] {.89}
154 [.05] {0}
-72 [.77] {.09}
-31 [.28] {.59}
14 [.15] {.85}
0 [.15] {.95}

484 [.02] {0}
117 [.13] {.02}
-48 [.41] {.36}
268 [.06] {0}
-107 [-2.91] {0}
-37 [.32] {.5}
4 [.19] {.95}
0 [.17] {.94}

649 [.02] {0}
204 [.15] {0}
-107 [-3.35] {.04}
365 [.08] {0}
-115 [-1.29] {0}
-32 [.39] {.7}
-17 [.31] {.83}
1 [.2] {.95}

891 [.02] {0}
272 [.31] {.38}
-131 [-1.19] {.19}
519 [.11] {0}
-85 [2.73] {.42}
19 [.49] {.95}
-39 [.8] {.76}
1 [.38] {.93}

0.95~0.98

Na√Øve Probit
2SLS
2SRI
2SRI - sres
2SRI - dres
2SRI - ares
2SRI - gres
Bi.Probit

203 [.02] {0}
-50 [.6] {.62}
40 [.1] {.23}
76 [.06] {0}
-4 [.22] {.96}
8 [.17] {.91}
35 [.1] {.32}
-3 [.24] {.94}

328 [.02] {0}
0 [.32] {.96}
33 [.14] {.60}
144 [.06] {0}
-42 [.44] {.66}
-10 [.23] {.94}
26 [.14] {.7}
-1 [.19] {.96}

549 [.02] {0}
111 [.19] {.26}
-29 [.36] {.78}
301 [.07] {0}
-89 [2.42] {.1}
-15 [.29] {.89}
19 [.21] {.91}
0 [.2] {.96}

819 [.03] {0}
259 [.17] {.02}
-128 [-.99] {.03}
444 [.09] {0}
-114 [-1.66] {.02}
-12 [.32] {.91}
-3 [.3] {.95}
0 [.22] {.97}

1292 [.04] {0}
482 [.25] {.13}
-164 [-.33] {.06}
679 [.12] {0}
-112 [-2.92] {.21}
30 [.49] {.97}
-36 [.82] {.8}
2 [.4] {.94}

2SRI ‚Äì sres: 2SRI with standardized residuals; 2SRI ‚Äì dres: 2SRI with deviance residuals; 2SRI ‚Äì ares: 2SRI with Anscombe residuals;
2SRI-gres: 2SRI with generalized residuals; Shaded cells highlight estimator with lowest percentage bias.
32

Table 4: Descriptive Statistics for HRS dataset
Binary Variables
Outcomes
Informal Care from Any Source
Informal Care from Child
Informal Care from other Relative
Home Health Care
Any Nursing Home Care
Treatment
LTCI coverage
IV
Subsidies
Other covariates
Marital status==2
Marital status ==3
Marital status==4
Female
No. of children==1
No. of children==2
No. of children==3
No. of children==4
No. of children==5
No. of children==6
Retired
Education category ==2
Education category ==3
Education category ==4
Income category==2
Income category==3
Race category ==2
Race category ==3
Fair/Poor health
Any ADL

Mean (sd)
0.60 (0.49)
0.43 (0.50)
0.165 (0.37)
0.068 ( 0.25)
0.023 (0.15)
0.157 (0.364)
0.335 (0.472)
0.11 (0.32)
0.17 (0.37)
0.06 (0.24)
0.56 (0.5)
0.1 (0.3)
0.31 (0.46)
0.22 (0.42)
0.13 (0.34)
0.15 (0.36)
0.01 (0.11)
0.47 (0.5)
0.35 (0.48)
0.26 (0.44)
0.3 (0.46)
0.36 (0.48)
0.64 (0.48)
0.06 (0.25)
0.03 (0.18)
0.17 (0.37)
0.1 (0.29)

33

Table 5:

Effects of long-term care insurance on different outcomes.

OutcomesÔÉ†

Informal Care from Any
Source

Informal Care from
Child

Informal Care from
other Relative

Home Health Care

Any Nursing Home
Care

Estimators

Pr(Y) = 0.60

Pr(Y) = 0.43

Pr(Y) = 0.165

Pr(Y) = 0.07

Pr(Y) = 0.023

Na√Øve Probit

-0.037 (0.006)++

-0.032 (0.006)++

-0.015 (0.004)++

-0.005 (0.003)

0.001 (0.002)

2SLS

-0.302 (0.165)+

-0.329 (0.165)++

0.161 (0.114)

-0.252 (0.089)++

0.087 (0.055)

2SRI

-0.319 (0.103)++

-0.238 (0.099)++

-0.091 (0.062)

-0.142 (0.031)++

0.063 (0.097)

2SRI - sres

-0.118 (0.029)++

-0.074 (0.029)++

-0.06 (0.017)++

-0.028 (0.013)++

0.008 (0.012)

2SRI - dres

-0.392 (0.085)++

-0.28 (0.082)++

-0.126 (0.052)++

-0.127 (0.032)++

0.072 (0.102)

2SRI - ares

-0.297 (0.07)++

-0.198 (0.068)++

-0.114 (0.038)++

-0.085 (0.026)++

0.038 (0.055)

2SRI ‚Äì gres

-0.268 (0.062)++

-0.179 (0.061)++

-0.111 (0.032)++

-0.077 (0.023)++

0.029 (0.041)

Bi.Probit

-0.283 (0.055)++

-0.179 (0.059)++

-0.147 (0.044)++

-0.117 (0.033)++

0.023 (0.028)

Pr(long-term care insurance) in these data = 0.157. 2SRI ‚Äì sres: 2SRI with standardized residuals; 2SRI ‚Äì dres: 2SRI with deviance
residuals; 2SRI ‚Äì ares: 2SRI with Anscombe residuals;
+
p-val‚â§ 0.10; ++ p-val‚â§0.05

34

